Could personalised medicine change treatment for migraine?The concept of personalised medicine is becoming established in cancer, with an increasing number of drugs targeting specific Share XCould personalised medicine change treatment for migraine?https://pharmaphorum.com/views-and-analysis/could-personalised-medicine-change-treatment-for-migraine/
Stress not a significant factor in migraine attacks, study findsNew findings from a digital study have challenged the belief that stress is a significant factor in triggering Share XStress not a significant factor in migraine attacks, study findshttps://pharmaphorum.com/news/stress-not-a-significant-factor-in-migraine-attacks-study-finds/
Novartis’ Aimovig tops topiramate in migraine face-offNovartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to Share XNovartis’ Aimovig tops topiramate in migraine face-offhttps://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/
Salvia’s migraine implant could be breakthrough, says FDAAn implantable neurostimulation migraine device from Salvia BioElectronics has gained Breakthrough Device Designation from the FDA. Traditional neurostimulation Share XSalvia’s migraine implant could be breakthrough, says FDAhttps://pharmaphorum.com/news/salvias-migraine-implant-could-be-breakthrough-says-fda/
Lundbeck tops Q3 expectations following strong sales of mental health drugsDenmark’s Lundbeck has beat its expectations in third quarter results, following a strong performance from its portfolio of Share XLundbeck tops Q3 expectations following strong sales of mental health drugshttps://pharmaphorum.com/news/lundbeck-tops-q3-expectations-following-strong-sales-of-mental-health-drugs/
Headache for Zosano as FDA turns down migraine patchZosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking Share XHeadache for Zosano as FDA turns down migraine patchhttps://pharmaphorum.com/news/headache-for-zosano-as-fda-turns-down-migraine-patch/
Salvia raises 26 million euros to finance migraine neurostimulation therapySalvia BioElectronics has raised 26 million euros ($30 million) in new financing to fund development of a neurostimulation Share XSalvia raises 26 million euros to finance migraine neurostimulation therapyhttps://pharmaphorum.com/news/salvia-raises-26-million-euros-to-finance-migraine-neurostimulation-therapy/
Satsuma pulped as acute migraine drug flunks phase 3 trialShares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed Share XSatsuma pulped as acute migraine drug flunks phase 3 trialhttps://pharmaphorum.com/news/satsuma-pulped-as-acute-migraine-drug-flunks-phase-3-trial/
Lundbeck announces plans to cut a fifth of R&D workforceLundbeck has announced plans to cut its research and development team, which could lead to a reduction of Share XLundbeck announces plans to cut a fifth of R&D workforcehttps://pharmaphorum.com/news/lundbeck-announces-plans-to-cut-around-160-rd-jobs/
